MXPA05011777A - Proteina cinasa c zeta como un farmaco blanco para la artritis y otras enfermadades inflamatorias. - Google Patents
Proteina cinasa c zeta como un farmaco blanco para la artritis y otras enfermadades inflamatorias.Info
- Publication number
- MXPA05011777A MXPA05011777A MXPA05011777A MXPA05011777A MXPA05011777A MX PA05011777 A MXPA05011777 A MX PA05011777A MX PA05011777 A MXPA05011777 A MX PA05011777A MX PA05011777 A MXPA05011777 A MX PA05011777A MX PA05011777 A MXPA05011777 A MX PA05011777A
- Authority
- MX
- Mexico
- Prior art keywords
- arthritis
- present
- zetapkc
- zeta
- expression
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se basa en el descubrimiento de que la expresion de ?PKC se incrementa en el tejido de pacientes artriticos en comparacion con los individuos normales. En consecuencia, la presente invencion proporciona metodos de diagnostico, pronostico y verificacion del curso de la artritis en un paciente basados en el incremento de la expresion del gen ?PKC en un tejido artritico. La presente invencion proporciona ademas compuestos que inhiben la expresion de ?PKC para uso como remedios en el tratamiento de la artritis, incluyendo, pero sin limitarse a, polinucleotidos y polipeptidos inhibidores, moleculas pequenas e inhibidores peptidicos. Ademas, la presente invencion proporciona formulaciones farmaceuticas y rutas de administracion para esos remedios, asi como metodos para evaluar su eficacia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46898703P | 2003-05-08 | 2003-05-08 | |
US49127403P | 2003-07-31 | 2003-07-31 | |
PCT/US2004/014759 WO2004104217A2 (en) | 2003-05-08 | 2004-05-10 | Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05011777A true MXPA05011777A (es) | 2006-01-26 |
Family
ID=33479253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05011777A MXPA05011777A (es) | 2003-05-08 | 2004-05-10 | Proteina cinasa c zeta como un farmaco blanco para la artritis y otras enfermadades inflamatorias. |
Country Status (9)
Country | Link |
---|---|
US (2) | US7638482B2 (es) |
EP (1) | EP1629283A2 (es) |
JP (1) | JP2007515940A (es) |
CN (1) | CN1860371B (es) |
AU (1) | AU2004242105B2 (es) |
BR (1) | BRPI0410071A (es) |
CA (1) | CA2525012A1 (es) |
MX (1) | MXPA05011777A (es) |
WO (1) | WO2004104217A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160062A1 (en) * | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
US20100196509A1 (en) | 2005-02-28 | 2010-08-05 | Jonathan Braun | Methods for Diagnosis and Treatment of Endometrial Cancer |
US8648052B2 (en) * | 2005-04-15 | 2014-02-11 | The Regents Of The University Of California | Prevention of chlamydia infection using SIRNA |
US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
WO2006113526A2 (en) | 2005-04-15 | 2006-10-26 | The Regents Of The University Of California | Prevention of chlamydia infection using a protective antibody |
JP5911805B2 (ja) | 2009-11-20 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 上皮膜タンパク質−2(emp2)および増殖性硝子体網膜症(pvr) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3731293A (en) * | 1992-02-24 | 1993-09-13 | Smithkline Beecham Corporation | Protein kinase c inhibitor |
US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6368831B1 (en) * | 1998-06-29 | 2002-04-09 | Childrens Hospital Los Angeles | Treatment of hyperproliferative disorders |
CN1158283C (zh) * | 1998-12-17 | 2004-07-21 | 霍夫曼-拉罗奇有限公司 | 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚 |
NZ515711A (en) * | 1999-06-24 | 2004-01-30 | Pharmacia Corp | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation |
ES2213996T3 (es) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
ATE289511T1 (de) * | 2000-12-18 | 2005-03-15 | Meiji Dairies Corp | Kavalactone als hemmer der tnf-alpha produktion |
-
2004
- 2004-05-10 US US10/842,142 patent/US7638482B2/en not_active Expired - Fee Related
- 2004-05-10 EP EP04751923A patent/EP1629283A2/en not_active Withdrawn
- 2004-05-10 MX MXPA05011777A patent/MXPA05011777A/es not_active Application Discontinuation
- 2004-05-10 CA CA002525012A patent/CA2525012A1/en not_active Abandoned
- 2004-05-10 CN CN2004800124155A patent/CN1860371B/zh not_active Expired - Fee Related
- 2004-05-10 BR BRPI0410071-9A patent/BRPI0410071A/pt not_active IP Right Cessation
- 2004-05-10 WO PCT/US2004/014759 patent/WO2004104217A2/en active Application Filing
- 2004-05-10 JP JP2006532963A patent/JP2007515940A/ja active Pending
- 2004-05-10 AU AU2004242105A patent/AU2004242105B2/en not_active Expired - Fee Related
-
2009
- 2009-11-11 US US12/616,484 patent/US20100062448A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1860371A (zh) | 2006-11-08 |
AU2004242105B2 (en) | 2009-05-28 |
US7638482B2 (en) | 2009-12-29 |
JP2007515940A (ja) | 2007-06-21 |
CN1860371B (zh) | 2010-11-24 |
WO2004104217A2 (en) | 2004-12-02 |
CA2525012A1 (en) | 2004-12-02 |
US20040259136A1 (en) | 2004-12-23 |
WO2004104217A3 (en) | 2005-11-24 |
US20100062448A1 (en) | 2010-03-11 |
EP1629283A2 (en) | 2006-03-01 |
AU2004242105A1 (en) | 2004-12-02 |
BRPI0410071A (pt) | 2006-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Burdette et al. | Gasdermin D in pyroptosis | |
US6362190B2 (en) | Method for treating inflammatory diseases by administering a thrombin inhibitor | |
ES2363019T3 (es) | Utilización de pirlindol para el tratamiento de las enfermedades que están caracterizadas por una proliferación de los linfocitos t y/o una hiperproliferación de queratinocitos en particular la dermatitis atópica y la psoriasis. | |
JP5785085B2 (ja) | 癒着を処置又は防止するためのポリペプチド | |
ES2956471T3 (es) | Tratamientos del angioedema hereditario | |
TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
KR20170122754A (ko) | 폐섬유증을 치료하기 위한 안지오텐신 ii 수용체 작용제 | |
RU2012147597A (ru) | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания | |
TW200735874A (en) | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure | |
HK1062923A1 (en) | Igf-binding protein-derived peptide | |
MXPA05011777A (es) | Proteina cinasa c zeta como un farmaco blanco para la artritis y otras enfermadades inflamatorias. | |
US9725484B2 (en) | Methods and compositions for the treatment of bone remodeling disorders | |
Chiu et al. | Poly-arginine peptide R18D reduces neuroinflammation and functional deficits following traumatic brain injury in the long-evans rat | |
TWI361694B (en) | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of sepsis or acute lung injury | |
Krause et al. | Successful treatment of hereditary angioedema with bradykinin B2‐receptor antagonist icatibant | |
KR101478925B1 (ko) | 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물 | |
WO2003053455A1 (en) | Surfactant prevention of lung complications from cancer chemotherapy | |
ES2930974T3 (es) | Compuesto (8ar, 12as, 13as) -5,8,8a, 9,10,11,12,12a,13,13a-decahidro-3-metoxi-12-(etilsulfonil)-6h-isoquino [2,1-g] [1,6] naftiridina para su uso en el tratamiento de psicosis | |
RU2564907C1 (ru) | Способ лечения больных красным плоским лишаем | |
EP4154899A1 (en) | Drug with prolonged analgesic action | |
US11820837B2 (en) | Modified peptides and associated methods of use | |
Cucereanu-Bădică et al. | The correlation between burn size and serum albumin level in the first 48 hours after burn injury | |
Kaur et al. | Hailey–Hailey disease: A case treated with topical tacrolimus | |
SHARMA et al. | An elderly lady with multiple blisters all over the body: hailey hailey disease | |
EA046469B1 (ru) | Средство пролонгированного анальгетического действия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |